Newsbenzinga
Immunome Clears Key Regulatory Milestone as Lead Drug Goes Under FDA Review
· Published
Article summary
FDA accepts Immunome's varegacestat NDA for desmoid tumors, with an April 28, 2027, PDUFA date backed by positive Phase 3 data.
An excerpt from the original article.
Comments —
Loading comments…